D. Boral Capital Initiates Coverage on Coya Therapeutics (NASDAQ:COYA)

Investment analysts at D. Boral Capital initiated coverage on shares of Coya Therapeutics (NASDAQ:COYA) in a research report issued on Wednesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $15.00 price target on the stock. D. Boral Capital’s price objective points to a potential upside of 150.84% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, November 11th.

Coya Therapeutics Stock Down 1.8 %

Shares of Coya Therapeutics stock opened at $5.98 on Wednesday. Coya Therapeutics has a 52-week low of $4.75 and a 52-week high of $10.69. The company has a 50 day moving average of $7.18 and a 200 day moving average of $6.79. The company has a market capitalization of $99.93 million, a P/E ratio of -9.37 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. As a group, research analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Insider Activity at Coya Therapeutics

In other news, CEO Arun Swaminathan acquired 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the transaction, the chief executive officer now directly owns 5,000 shares in the company, valued at approximately $36,700. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have bought a total of 9,510 shares of company stock worth $69,615 in the last three months. Insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after buying an additional 4,485 shares in the last quarter. GHP Investment Advisors Inc. purchased a new stake in shares of Coya Therapeutics in the 3rd quarter worth about $169,000. Renaissance Technologies LLC purchased a new stake in shares of Coya Therapeutics in the 2nd quarter worth about $101,000. Gilbert & Cook Inc. purchased a new stake in shares of Coya Therapeutics in the 2nd quarter worth about $61,000. Finally, Vanguard Group Inc. raised its stake in Coya Therapeutics by 772.3% in the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after purchasing an additional 750,338 shares during the last quarter. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.